.. Résultats-obtenus-au-laboratoire, 59 2.1. Résultats in vitro, p.60

A. Brandes, A. Tosoni, E. Franceschi, M. Reni, and G. Gatta, Glioblastoma in adults, Critical Reviews in Oncology/Hematology, vol.67, issue.2, pp.139-152, 2008.
DOI : 10.1016/j.critrevonc.2008.02.005

H. Ohgaki and P. Kleihues, Epidemiology and etiology of gliomas, Acta Neuropathologica, vol.43, issue.1, pp.93-108, 2005.
DOI : 10.1007/s00401-005-0991-y

H. Ohgaki, P. Dessen, B. Jourde, S. Horstmann, T. Nishikawa et al., Genetic Pathways to Glioblastoma: A Population-Based Study, Cancer Research, vol.64, issue.19, pp.6892-6899, 2004.
DOI : 10.1158/0008-5472.CAN-04-1337

H. Ohgaki and K. , Population-Based Studies on Incidence, Survival Rates, and Genetic Alterations in Astrocytic and Oligodendroglial Gliomas, Journal of Neuropathology & Experimental Neurology, vol.64, issue.6, pp.479-489, 2005.
DOI : 10.1093/jnen/64.6.479

D. Xie, Y. Zeng, H. Wang, J. Wen, Y. Tao et al., Expression of cytoplasmic and nuclear Survivin in primary and secondary human glioblastoma, British Journal of Cancer, vol.6, issue.1, pp.108-114, 2006.
DOI : 10.1006/gyno.1997.4783

L. Stewart, Chemotherapy in adult high-grade glioma : a systematic review and meta-analysis of individual patient data from 12 randomised trials, Lancet, vol.359, pp.1011-1029, 2002.

J. Wong, J. Provenzale, and J. Petrella, Perfusion MR Imaging of Brain Neoplasms, American Journal of Roentgenology, vol.174, issue.4, pp.1147-57, 2000.
DOI : 10.2214/ajr.174.4.1741147

H. Fujisawa, R. Reis, M. Nakamura, S. Colella, Y. Yonekawa et al., Loss of Heterozygosity on Chromosome 10 Is More Extensive in Primary (De Novo) Than in Secondary Glioblastomas, Laboratory Investigation, vol.13, issue.1, pp.65-72, 2000.
DOI : 10.1038/labinvest.3780009

D. Bigner, Chromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25, Oncogene, vol.10, pp.2243-2246, 1995.

K. Ichimura, E. Schmidt, A. Miyakawa, H. Goike, and V. Collins, Distinct patterns of deletion on 10p and 10q suggest involvement of multiple tumor suppressor genes in the development of astrocytic gliomas of different malignancy grades, Genes, Chromosomes and Cancer, vol.77, issue.1, pp.9-15, 1998.
DOI : 10.1002/(SICI)1098-2264(199805)22:1<9::AID-GCC2>3.0.CO;2-1

M. Nakamura, T. Watanabe, U. Klangby, C. Asker, K. Wiman et al., p14ARF Deletion and Methylation in Genetic Pathways to Glioblastomas, Brain Pathology, vol.18, issue.2
DOI : 10.1111/j.1750-3639.2001.tb00388.x

W. Biernat, Y. Tohma, Y. Yonekawa, P. Kleihues, and H. Ohgaki, Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas, Acta Neuropathologica, vol.94, issue.4
DOI : 10.1007/s004010050711

W. Curran, . Jr, C. Scott, and J. Horton, Recursive Partitioning Analysis of Prognostic Factors in Three Radiation Therapy Oncology Group Malignant Glioma Trials, JNCI Journal of the National Cancer Institute, vol.85, issue.9, pp.704-710, 1993.
DOI : 10.1093/jnci/85.9.704

M. Prados, Age and radiation response in glioblastoma multiforme

G. Keles, K. Lamborn, S. Chang, M. Prados, and M. Berger, Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy, Journal of Neurosurgery, vol.100, issue.1, pp.41-47, 2004.
DOI : 10.3171/jns.2004.100.1.0041

J. Hekmatpanah, Quantitative imaging study of extent of surgical resection and prognosis of malignant astrocytomas, Neurosurgery, vol.41, issue.5, pp.1028-1064, 1997.

M. Quigley, J. Maroon, and . Neurosurgery, The relationship between survival and the extent of the resection in patients with supratentorial malignant gliomas

V. Vuorinen, S. Hinkka, M. Färkkilä, and J. Jääskeläinen, Debulking or biopsy of malignant glioma in elderly people - a randomised study, Acta Neurochirurgica, vol.145, issue.1
DOI : 10.1007/s00701-002-1030-6

B. Huu, Nimustine (ACNU) plus teniposide (VM26) in recurrent glioblastoma, Oncology, vol.76, issue.3, pp.184-193, 2009.

R. Djedid, O. Tomasi, A. Haidara, M. Rynkowski, and F. Lefranc, Glioblastoma treatment in 2010, Rev Med Brux, vol.30, issue.5, pp.496-505, 2009.

E. Franceschi, G. Cavallo, and S. Lonardi, Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO), British Journal of Cancer, vol.2, issue.7, pp.1047-51, 2007.
DOI : 10.1126/science.1101637

P. Brown, . Ks, J. Sarkaria, and W. Wu, A phase II trial (N0177) of erlotinib and temozolomide (TMZ) combined with radiation therapy (RT) in glioblastoma multiforme (GBM), Journal of Clinical Oncology, vol.26, issue.15_suppl, 2008.
DOI : 10.1200/jco.2008.26.15_suppl.2016

I. Mellinghoff, M. Wang, and I. Vivanco, Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors, New England Journal of Medicine, vol.353, issue.19, pp.2012-2024, 2005.
DOI : 10.1056/NEJMoa051918

D. Haas-kogan, M. Prados, and T. Tihan, Epidermal Growth Factor Receptor, Protein Kinase B/Akt, and Glioma Response to Erlotinib, JNCI Journal of the National Cancer Institute, vol.97, issue.12, pp.880-887, 2005.
DOI : 10.1093/jnci/dji161

B. Neyns, J. Sadones, and E. Joosens, Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma, Annals of Oncology, vol.20, issue.9, pp.1596-1603, 2009.
DOI : 10.1093/annonc/mdp032

A. Ostman, PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma, Cytokine & Growth Factor Reviews, vol.15, issue.4, pp.275-86, 2004.
DOI : 10.1016/j.cytogfr.2004.03.002

G. Dresemann, Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series, Annals of Oncology, vol.16, issue.10, pp.1702-1710, 2005.
DOI : 10.1093/annonc/mdi317

D. Reardon, M. Egorin, and J. Quinn, Phase II Study of Imatinib Mesylate Plus Hydroxyurea in Adults With Recurrent Glioblastoma Multiforme, Journal of Clinical Oncology, vol.23, issue.36
DOI : 10.1200/JCO.2005.03.2185

C. Knobbe, J. Reifenberger, and G. Reifenberger, Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas, Acta Neuropathologica, vol.17, issue.6, pp.467-70, 2004.
DOI : 10.1007/s00401-004-0929-9

S. Rao, D. Cunningham, and A. De-gramont, Phase III Double-Blind Placebo-Controlled Study of Farnesyl Transferase Inhibitor R115777 in Patients With Refractory Advanced Colorectal Cancer, Journal of Clinical Oncology, vol.22, issue.19, pp.3950-3957, 2004.
DOI : 10.1200/JCO.2004.10.037

E. Van-cutsem, H. Van-de-velde, and P. Karasek, Phase III Trial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic Cancer, Journal of Clinical Oncology, vol.22, issue.8, pp.1430-1438, 2004.
DOI : 10.1200/JCO.2004.10.112

E. Jane, D. Premkumar, and I. Pollack, Coadministration of Sorafenib with Rottlerin Potently Inhibits Cell Proliferation and Migration in Human Malignant Glioma Cells, Journal of Pharmacology and Experimental Therapeutics, vol.319, issue.3, pp.1070-1080, 2006.
DOI : 10.1124/jpet.106.108621

S. Sathornsumetee, A. Hjelmeland, and S. Keir, AAL881, a Novel Small Molecule Inhibitor of RAF and Vascular Endothelial Growth Factor Receptor Activities, Blocks the Growth of Malignant Glioma, Cancer Research, vol.66, issue.17, pp.8722-8730, 2006.
DOI : 10.1158/0008-5472.CAN-06-0284

W. Couldwell, J. Uhm, J. Antel, and V. Yong, Enhanced Protein Kinase C Activity Correlates with the Growth Rate of Malignant Gliomas in Vitro, Neurosurgery, vol.29, issue.6
DOI : 10.1227/00006123-199112000-00013

K. Keyes, L. Mann, and M. Sherman, LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice, Cancer Chemotherapy and Pharmacology, vol.53, issue.2, pp.133-140, 2004.
DOI : 10.1007/s00280-003-0713-x

M. Kazmierski, Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study, Neuro Oncol, vol.12, issue.6, pp.608-621, 2010.

L. Cher, Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma, J Clin Oncol, vol.28, issue.7, pp.1168-74, 2010.

J. Nakamura, A. Karlsson, and N. Arvold, PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas, Journal of Neuro-Oncology, vol.7, issue.3, pp.215-237, 2005.
DOI : 10.1007/s11060-004-1718-y

L. De-la-pena, W. Burgan, and D. Carter, Inhibition of Akt by the alkylphospholipid perifosine does not enhance the radiosensitivity of human glioma cells, Molecular Cancer Therapeutics, vol.5, issue.6, pp.1504-1514, 2006.
DOI : 10.1158/1535-7163.MCT-06-0091

J. Herndon, Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma, J Neurooncol, vol.96, issue.2, pp.219-249, 2010.

E. Galanis, J. Buckner, and M. Maurer, Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study, Journal of Clinical Oncology, vol.23, issue.23, pp.5294-5304, 2005.
DOI : 10.1200/JCO.2005.23.622

S. Chang, P. Wen, and T. Cloughesy, Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme, Investigational New Drugs, vol.19, issue.4, pp.357-361, 2005.
DOI : 10.1007/s10637-005-1444-0

T. Kreisl, A. Lassman, P. Mischel, N. Rosen, H. Scher et al., A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM), Journal of Neuro-Oncology, vol.66, issue.1, pp.99-105, 2009.
DOI : 10.1007/s11060-008-9741-z

K. Plate, G. Breier, H. Weich, and W. Risau, Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo, Nature, vol.359, issue.6398
DOI : 10.1038/359845a0

K. Kim, B. Li, J. Winer, M. Armanini, N. Gillett et al., Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo, Nature, vol.362, issue.6423, pp.841-844, 1993.
DOI : 10.1038/362841a0

R. Dinapoli, Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma, Int J Radiat Oncol Biol Phys, vol.40, issue.2, pp.297-302, 1998.

J. Takahashi, A multicenter phase I trial of combination therapy with interferon-? and temozolomide for high-grade gliomas (INTEGRA study): the final report, J Neurooncol, vol.104, issue.2, pp.573-580, 2011.

H. Colman, B. Berkey, M. Maor, M. Groves, C. Schultz et al., Phase II Radiation Therapy Oncology Group trial of conventional radiation therapy followed by treatment with recombinant interferon-?? for supratentorial glioblastoma: Results of RTOG 9710, International Journal of Radiation Oncology*Biology*Physics, vol.66, issue.3, pp.818-842, 2006.
DOI : 10.1016/j.ijrobp.2006.05.021

J. Masferrer, K. Leahy, and A. Koki, Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors, Cancer Res, vol.60, pp.1306-1311, 2000.

D. Reardon, J. Quinn, J. Vredenburgh, J. Rich, S. Gururangan et al., Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma, Cancer, vol.83, issue.2, pp.329-367, 2005.
DOI : 10.1002/cncr.20776

S. Harland, R. Kuc, J. Pickard, and A. Davenport, Characterization of Endothelin Receptors in Human Brain Cortex, Gliomas, and Meningiomas, Journal of Cardiovascular Pharmacology, vol.26, pp.408-419, 1995.
DOI : 10.1097/00005344-199506263-00120

S. Phuphanich, K. Carson, and S. Grossman, Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma, Neuro-Oncology, vol.10, issue.4, pp.617-623, 2008.
DOI : 10.1215/15228517-2008-013

R. Johnstone, HISTONE-DEACETYLASE INHIBITORS: NOVEL DRUGS FOR THE TREATMENT OF CANCER, Nature Reviews Drug Discovery, vol.19, issue.4, pp.287-99, 2002.
DOI : 10.1074/jbc.274.44.31127

E. Galanis, K. Jaeckle, M. Maurer, J. Reid, M. Ames et al., Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study, Journal of Clinical Oncology, vol.27, issue.12, pp.2052-2060, 2009.
DOI : 10.1200/JCO.2008.19.0694

P. Chinnaiyan, S. Chowdhary, L. Potthast, A. Prabhu, Y. Tsai et al., Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma, Neuro-Oncology, vol.14, issue.1, pp.93-100, 2012.
DOI : 10.1093/neuonc/nor187

S. Phuphanich, J. Supko, and K. Carson, Phase I trial of bortezomib in adults with recurrent malignant glioma, Proc Am Soc Clin Oncol, vol.24, p.1567, 2006.

F. Lang, W. Yung, R. Sawaya, and P. Tofilon, Adenovirus-mediated p53 Gene Therapy for Human Gliomas, Neurosurgery, vol.45, issue.5, pp.1093-1104, 1999.
DOI : 10.1097/00006123-199911000-00016

R. Steinman, The Dendritic Cell System and its Role in Immunogenicity, Annual Review of Immunology, vol.9, issue.1
DOI : 10.1146/annurev.iy.09.040191.001415

J. Yu, G. Liu, H. Ying, W. Yong, K. Black et al., Vaccination with Tumor Lysate-Pulsed Dendritic Cells Elicits Antigen-Specific, Cytotoxic T-Cells in Patients with Malignant Glioma, Cancer Research, vol.64, issue.14, pp.4973-4979, 2004.
DOI : 10.1158/0008-5472.CAN-03-3505

R. Yamanaka, J. Homma, N. Yajima, N. Tsuchiya, M. Sano et al., Clinical Evaluation of Dendritic Cell Vaccination for Patients with Recurrent Glioma: Results of a Clinical Phase I/II Trial, Clinical Cancer Research, vol.11, issue.11, pp.4160-4167, 2005.
DOI : 10.1158/1078-0432.CCR-05-0120

D. Vleeschouwer, S. Fieuws, S. Rutkowski, S. Van-calenbergh, F. Van-loon et al., Postoperative Adjuvant Dendritic Cell-Based Immunotherapy in Patients with Relapsed Glioblastoma Multiforme, Clinical Cancer Research, vol.14, issue.10, pp.3098-104, 2008.
DOI : 10.1158/1078-0432.CCR-07-4875

D. Vecchio, C. Wong, and A. , Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiform, Curr Opin Mol Ther, vol.12, pp.741-54, 2010.

R. Derynck, Production of transforming growth factor beta by human T ! ! 90 ! lymphocytes and its potential role in the regulation of T cell growth, J Exp Med, vol.163, issue.5, pp.1037-1050, 1986.

S. Ludwig, Results of a phase Iib active-controlled study with AP 12009 for patients with recurrent or refractory anaplastic astrocytoma, ASCO Meeting Abstracts, vol.26, issue.15, p.2076, 2008.

A. Suri, Trabedersen Glioma Study Group Targeted therapy for highgrade glioma with the TGF-?2 inhibitor trabedersen: results of a randomized and controlled phase IIb study, Neuro Oncol, vol.13, issue.1, pp.132-174, 2011.

W. Debinski, D. Gibo, S. Hulet, J. Connor, and G. Gillespie, Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas

M. Kawakami, K. Kawakami, and R. Puri, Intratumor administration of interleukin 13 receptor-targeted cytotoxin induces apoptotic cell death in human malignant glioma tumor xenografts, Mol Cancer Ther, vol.1, issue.12, pp.999-1007, 2002.

S. Kunwar, S. Chang, M. Westphal, M. Vogelbaum, J. Sampson et al., Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma, Neuro-Oncology, vol.12, issue.8, pp.871-81, 2010.
DOI : 10.1093/neuonc/nop054

S. Sathornsumetee, D. Reardon, A. Desjardins, J. Quinn, J. Vredenburgh et al., Molecularly targeted therapy for malignant glioma, Cancer, vol.444, issue.1, pp.13-24, 2007.
DOI : 10.1002/cncr.22741

D. Chao and S. Korsmeyer, BCL-2 FAMILY: Regulators of Cell Death, Annual Review of Immunology, vol.16, issue.1, pp.395-419, 1998.
DOI : 10.1146/annurev.immunol.16.1.395

P. Li, D. Nijhawan, I. Budihardjo, S. Srinivasula, M. Ahmad et al., Cytochrome c and dATP-Dependent Formation of Apaf-1/Caspase-9 Complex Initiates an Apoptotic Protease Cascade, Cell, vol.91, issue.4, pp.479-89, 1997.
DOI : 10.1016/S0092-8674(00)80434-1

A. Kelekar, B. Chang, J. Harlan, S. Fesik, and C. Thompson, Bad is a BH3 domain-containing protein that forms an inactivating dimer with Bcl-XL., Molecular and Cellular Biology, vol.17, issue.12, pp.7040-7046, 1997.
DOI : 10.1128/MCB.17.12.7040

J. Zha, H. Harada, K. Osipov, J. Jockel, G. Waksman et al., BH3 Domain of BAD Is Required for Heterodimerization with BCL-XL and Pro-apoptotic Activity, Journal of Biological Chemistry, vol.272, issue.39, pp.24101-24105, 1997.
DOI : 10.1074/jbc.272.39.24101

L. Walensky, BCL-2 in the crosshairs: tipping the balance of life and death, Cell Death and Differentiation, vol.3, issue.8, pp.1339-50, 2006.
DOI : 10.1073/pnas.87.10.3660

V. Torchilin, Recent advances with liposomes as pharmaceutical carriers, Nature Reviews Drug Discovery, vol.103, issue.2
DOI : 10.1081/LPR-120017488

A. Klibanov, K. Maruyama, V. Torchilin, and L. Huang, Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes, FEBS Letters, vol.3, issue.1, pp.235-238, 1990.
DOI : 10.1016/0014-5793(90)81016-H

H. Maeda, J. Wu, T. Sawa, Y. Matsumura, and K. Hori, Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review, Journal of Controlled Release, vol.65, issue.1-2, pp.271-84, 2000.
DOI : 10.1016/S0168-3659(99)00248-5

L. Liguori and J. Lenormand, Production of Recombinant Proteoliposomes for Therapeutic Uses, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00821163

U. Pichlmeier, A. Bink, G. Schackert, and W. Stummer, Resection and survival in glioblastoma multiforme: An RTOG recursive partitioning analysis of ALA study patients, Neuro-Oncology, vol.10, issue.6, pp.1025-1034, 2008.
DOI : 10.1215/15228517-2008-052

J. Clarke, F. Iwamoto, J. Sul, K. Panageas, A. Lassman et al., Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Temozolomide for Newly Diagnosed Glioblastoma, Journal of Clinical Oncology, vol.27, issue.23, pp.3861-3868, 2009.
DOI : 10.1200/JCO.2008.20.7944

J. Quinn, S. Jiang, D. Reardon, A. Desjardins, J. Vredenburgh et al., -Benzylguanine in Adults With Recurrent, Temozolomide-Resistant Malignant Glioma, Journal of Clinical Oncology, vol.27, issue.8, pp.1262-1269, 2009.
DOI : 10.1200/JCO.2008.18.8417

URL : https://hal.archives-ouvertes.fr/in2p3-00460536

M. Javle and N. Curtin, The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy, Therapeutic Advances in Medical Oncology, vol.70, issue.6, pp.257-67, 2011.
DOI : 10.1056/NEJMoa1011418